成人接受体外生命支持患者的真菌感染
该回顾性队列研究利用体外生命支持组织注册数据库,纳入2006至2016年间接受任何模式ECMO的成人患者,评估真菌感染(定植或感染)的患病率、危险因素和预后。共2129例(10.8%)存在真菌定植或感染;曲霉受累272例(1.4%),存活出院率35.7%;念珠菌侵袭性血流感染245例(1.2%),存活率35.9%。曲霉受累的危险因素包括实体器官移植、呼吸支持和流感感染;念珠菌血症的危险因素包括脓毒症和肾脏替代治疗。多变量分析显示,曲霉受累和念珠菌血症均与生存率降低独立相关。
要点
- ECMO成人中真菌定植或感染占10.8%(2129例),曲霉受累占1.4%(272例),念珠菌侵袭性血流感染占1.2%(245例)。
- 曲霉受累患者存活出院率为35.7%,念珠菌侵袭性血流感染患者存活率为35.9%。
- 曲霉受累的危险因素:实体器官移植(OR 1.83;p=0.008)、呼吸支持(OR 2.75;p<0.001)、流感感染(OR 2.48;p<0.001)。
- 念珠菌血症的危险因素:脓毒症(OR 1.60;p=0.005)、肾脏替代治疗(OR 1.55;p=0.007)。
- 多变量分析中,曲霉受累(OR 0.40;p<0.001)和念珠菌血症(OR 0.47;p<0.001)均与生存率降低独立相关。
适用人群与场景
- 2006至2016年间接受任何模式ECMO的成人患者,且诊断为真菌感染或真菌培养阳性。
研究设计与关键结果
- 研究类型:回顾性队列研究,使用体外生命支持组织注册数据库(来自数百个国际中心)。
- 样本量:2129例成人患者(10.8%)存在真菌定植或感染。
- 曲霉受累(定植或感染)272例(1.4%),存活出院率35.7%。
- 念珠菌侵袭性血流感染245例(1.2%),存活率35.9%。
- 曲霉受累危险因素:实体器官移植(OR 1.83;p=0.008)、呼吸支持(OR 2.75;p<0.001)、流感感染(OR 2.48;p<0.001)。
- 念珠菌血症危险因素:脓毒症(OR 1.60;p=0.005)、肾脏替代治疗(OR 1.55;p=0.007)。
- 多变量分析:曲霉受累(OR 0.40;p<0.001)和念珠菌血症(OR 0.47;p<0.001)均与生存率降低独立相关。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文结论指出,ECMO患者中曲霉受累和念珠菌侵袭性血流感染的患病率并不高于一般ICU人群所报告的水平。
- 原文结论指出,曲霉受累和念珠菌血症均与生存率降低独立相关。
- 原文结论指出,曲霉受累与因呼吸支持而使用ECMO及流感感染强烈相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Patients on extracorporeal membrane oxygenation (ECMO) are often among the most severely ill in the intensive care unit. They are often receiving broad-spectrum antibiotics; they have multiple entry points for pathogens; and their immune system is impaired by blood circuit interaction. These factors are thought to predispose them to fungal infections. We thus aimed to evaluate the prevalence, risk factors, and prognosis of fungal infections in adults on ECMO.
METHODS: We conducted a retrospective cohort study using the Extracorporeal Life Support Organization registry, which compiles data on ECMO use from hundreds of international centers. We included all adult patients from 2006 to 2016 on any mode of ECMO with either a diagnosis of fungal infection or a positive fungal culture.
RESULTS: Our study comprised 2129 adult patients (10.8%) with fungal colonization or infection. Aspergillus involvement (colonization or infection) was present in 272 patients (1.4%), of whom 35.7% survived to hospital discharge. There were 245 patients (1.2%) with Candida invasive bloodstream infection, with 35.9% survival. Risk factors for Aspergillus involvement included solid organ transplant (OR 1.83; p = 0.008), respiratory support (OR 2.75; p < 0.001), and influenza infection (OR 2.48; p < 0.001). Risk factors for candidemia included sepsis (OR 1.60; p = 0.005) and renal replacement therapy (OR 1.55; p = 0.007). In multivariable analysis, Aspergillus involvement (OR 0.40; p < 0.001) and candidemia (OR 0.47; p < 0.001) were both independently associated with decreased survival.
CONCLUSIONS: The prevalence of Aspergillus involvement and Candida invasive bloodstream infection were not higher in patients on ECMO than what has been reported in the general intensive care population. Both were independently associated with a reduced survival. Aspergillus involvement was strongly associated with ECMO for respiratory support and influenza.
参考来源
- Cavayas YA, Yusuff H, Porter R, et al. Fungal infections in adult patients on extracorporeal life support. Crit Care. 2018. PMID: 29665838. doi:10.1186/s13054-018-2023-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。